Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small-cell lung cancer with a PD-L1 expression level of >= 1% by the USA Food and Drug Administration

G. Mountzios; J. Remon; S. Novello; N. Blais; R. Califano; T. Cufer; A. M. Dingemans; S. V. Liu; N. Peled; N. A. Pennell; M. Reck; C. Rolfo; D. Tan; J. Vansteenkiste; H. West; B. Besse

doi:10.1093/annonc/mdz295

Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small-cell lung cancer with a PD-L1 expression level of >= 1% by the USA Food and Drug Administration

G. Mountzios^*, J. Remon, S. Novello, N. Blais, R. Califano, T. Cufer, A. M. Dingemans, S. V. Liu, N. Peled, N. A. Pennell, M. Reck, C. Rolfo, D. Tan, J. Vansteenkiste, H. West, B. Besse

^*Corresponding author for this work

Research output: Contribution to journal › Editorial › Academic › peer-review

9 Citations (Web of Science)

Original language	English
Pages (from-to)	1686-1688
Number of pages	3
Journal	Annals of Oncology
Volume	30
Issue number	11
DOIs	https://doi.org/10.1093/annonc/mdz295
Publication status	Published - Nov 2019

Keywords

NIVOLUMAB
DOCETAXEL
1ST-LINE

Access to Document

10.1093/annonc/mdz295

Cite this

Mountzios, G., Remon, J., Novello, S., Blais, N., Califano, R., Cufer, T., Dingemans, A. M., Liu, S. V., Peled, N., Pennell, N. A., Reck, M., Rolfo, C., Tan, D., Vansteenkiste, J., West, H., & Besse, B. (2019). Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small-cell lung cancer with a PD-L1 expression level of >= 1% by the USA Food and Drug Administration. Annals of Oncology, 30(11), 1686-1688. https://doi.org/10.1093/annonc/mdz295

@article{b11276925de3431385a4292159d43006,

title = "Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small-cell lung cancer with a PD-L1 expression level of >= 1% by the USA Food and Drug Administration",

keywords = "NIVOLUMAB, DOCETAXEL, 1ST-LINE",

author = "G. Mountzios and J. Remon and S. Novello and N. Blais and R. Califano and T. Cufer and Dingemans, {A. M.} and Liu, {S. V.} and N. Peled and Pennell, {N. A.} and M. Reck and C. Rolfo and D. Tan and J. Vansteenkiste and H. West and B. Besse",

year = "2019",

month = nov,

doi = "10.1093/annonc/mdz295",

language = "English",

volume = "30",

pages = "1686--1688",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

number = "11",

}

Mountzios, G, Remon, J, Novello, S, Blais, N, Califano, R, Cufer, T, Dingemans, AM, Liu, SV, Peled, N, Pennell, NA, Reck, M, Rolfo, C, Tan, D, Vansteenkiste, J, West, H & Besse, B 2019, 'Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small-cell lung cancer with a PD-L1 expression level of >= 1% by the USA Food and Drug Administration', Annals of Oncology, vol. 30, no. 11, pp. 1686-1688. https://doi.org/10.1093/annonc/mdz295

Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small-cell lung cancer with a PD-L1 expression level of >= 1% by the USA Food and Drug Administration. / Mountzios, G.; Remon, J.; Novello, S. et al.
In: Annals of Oncology, Vol. 30, No. 11, 11.2019, p. 1686-1688.

Research output: Contribution to journal › Editorial › Academic › peer-review

TY - JOUR

T1 - Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small-cell lung cancer with a PD-L1 expression level of >= 1% by the USA Food and Drug Administration

AU - Mountzios, G.

AU - Remon, J.

AU - Novello, S.

AU - Blais, N.

AU - Califano, R.

AU - Cufer, T.

AU - Dingemans, A. M.

AU - Liu, S. V.

AU - Peled, N.

AU - Pennell, N. A.

AU - Reck, M.

AU - Rolfo, C.

AU - Tan, D.

AU - Vansteenkiste, J.

AU - West, H.

AU - Besse, B.

PY - 2019/11

Y1 - 2019/11

KW - NIVOLUMAB

KW - DOCETAXEL

KW - 1ST-LINE

U2 - 10.1093/annonc/mdz295

DO - 10.1093/annonc/mdz295

M3 - Editorial

C2 - 31504132

SN - 0923-7534

VL - 30

SP - 1686

EP - 1688

JO - Annals of Oncology

JF - Annals of Oncology

IS - 11

ER -

Mountzios G, Remon J, Novello S, Blais N, Califano R, Cufer T et al. Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small-cell lung cancer with a PD-L1 expression level of >= 1% by the USA Food and Drug Administration. Annals of Oncology. 2019 Nov;30(11):1686-1688. doi: 10.1093/annonc/mdz295